Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8555215 | 0.89 | POLB (0.61) | POLBKMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL27946037 | 0.86 | POLB (0.58) | POLBKMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL7261188 | 0.85 | POLB (0.65) | POLBKMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL7260513 | 0.83 | POLB (0.61) | POLBKMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL1413618 | 0.78 | KMT2A (0.58) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL7256728 | 0.78 | POLB (0.55) | POLBKMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL20346311 | 0.76 | MAPT (0.48) | POLBKMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL6756690 | 0.75 | POLB (1.00) | POLBMAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL31232896 | 0.75 | POLB (1.00) | POLBMAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL7160912 | 0.74 | POLB (0.68) | POLBKMT2AMAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1386912-B1 | CYCLIC AMIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-7476688-B2 | Cyclic amidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-13 | — | — | US | disclosed |
| US-20040254376-A1 | Cyclic amidine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1386912-A1 | CYCLIC AMIDINE DERIVATIVE | Eisai Co., Ltd. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-4233440-A | OPTICAL BRIGHTENERS | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254376-A1 | Cyclic amidine derivative | ARGLU1, ARG1, PRMT1 | POLB 4577/4885KMT2A 1267/4885MAPT 4592/4885 |
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | H1-10, H1-3, H1-4 | POLB 4743/4885KMT2A 2585/4885MAPT 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.